T1	Participants 50 98	in patients with pulmonary arterial hypertension
T2	Participants 171 225	in patients with pulmonary arterial hypertension (PAH)
T3	Participants 496 583	randomized patients with PAH to receive placebo or sitaxsentan 50 or 100Â mg once daily
T4	Participants 888 967	RESULTS Of 98 randomized patients, 61% were WHO functional class II at baseline
T5	Participants 1654 1721	not 6MWD in PAH patients who were mostly WHO functional class II at
